Balchem: It's A Buy From Me After Posting Strong Q2 Results

Balchem Corporation posted Q2 results, with EPS of $1.49 beating estimates by $0.07, while surpassing the consensus by $15M and was up 11% YoY. All areas of the business posted impressive results, as the minimum revenue growth for a segment was 8.9%, while the peak was 15% in Animal Nutrition & Health. The stock appears to be trading for a ~9% discount to its fair value right now based on my FCF valuation model.

Balchem Corporation (BCPC) looks to be trading for an appealing valuation at this time while providing investors with an estimated forward return north of 11%. BCPC just announced their Q2 2026 earnings, with all